Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bristol Myers will be the partner for the new Oncosec TNBC phase II trial for sure. You can bet they already agreed to the combo trial months ago. Remember the Confidential treatment order filed recently? There was a lot of lingo in the document about drug supply agreements and Merck's desire to be informed if any other companies would enter into drug supply agreements with Oncosec. This TNBC release today confirms that another player, BMY is now in the picture. I am positive Merck will be doing the Head and Neck trial with Oncosec. This is all going to get very interesting. We will await the details of the new collaboration Oncosec has with Bristol Myers.
Just need some more news to get us over that $2 mark.
Bio shakeout. I have been in Oncosec too long on the great potential to be shaken out though. When those temporary drops happen I don't even flinch, because we bounce right back. 2018 is going to be a great year for Oncosec.
Such market manipulation. Would not be surprised to see Oncosec at $2.20 this afternoon. We were just about to breakout over $2 the last few days. Patience folks, and don't panic sell....you will regret it later this year.
TNBC data on the pilot study should be released soon. Who will be partnering (with money?...drug supply details) is the question. We know the data will be positive. I think we see a nice boost in share price.
What is going to happen next will be:
1-TNBC pilot study data release
2-Initiation of phase II TNBC study with anti-pd1 collaboration/partner (Merck or BMY?)
3-Initiation of 2 new IST trials with anti-pd1 collaboration/partner (Merck or BMY?) One will be Head and Neck cancer.
The details of any of these new trials could boost the share price.
TNBC pilot study data should give Oncosec a boost. The data must be positive or they would not initiate a phase II combo study.
Mid 2018 is the expected release of interim PISCES data.
Yes, definitely a shakeout. Fools will sell.
Merck hitting it out of the ballpark today in NSCLC. Good PISCES data in 2018 for Oncosec could also lead to a combo study with Merck in NSCLC. That would be a huge opportunity for both companies in the anti-pd1 failure population.
Any pullback now in share price is a buying opportunity. Oncosec is setting the stage in 2018 for price appreciation, pipeline expansion, and licensing deals or Buyout. All riding on PISCES data now. I believe it will be a success and the rest will be history. Bullish year ahead!
The move today is more likely related to the Shareholder meeting happening tomorrow and all the possible trial announcements happening in 2018. PISCES data, collaborations/licensing deals related to the new trials. Will trials be solely with Merck or other Pharmas involved. Possible multi-gene construct collaboration announcement. A lot is going to be happening in 2018. Announcement of the new TNBC trial even before the pilot TNBC data has been released is very Bullish. 2018 I think is only going to be the beginning of great things to come for Oncosec.
HC Wainwright Target is $12. DMPI has bottomed around January for the last two years and then made strong moves to the upside. Looks like the same trend again this year.
https://www.americanbankingnews.com/2017/11/29/hc-wainwright-analysts-give-delmar-pharmaceuticals-dmpi-a-12-00-price-target.html
The dedicated PISCES link went up this past week. I think with so many positive developments on the horizon, Oncosec should really update their entire website. The site is a bit disorganized with too many repeated links scattered. As a graphic artist and investor, I find that when a company spends the time and money to publish a professional looking website it goes a long way in presenting a positive image. I think that 2018 is going to be a great year for Oncosec and investors that are new to their story should be hit with the WOW factor when visiting the website for the first time. Just my opinion of course and I think it will be a great year regardless of the look of the website.
Looks and Feels very good.....and very real....finally!
The difference this time is that Dan O'Connor is interested in the financial aspect of this company as well as the science.
I believe they will be at J.P. Morgan Healthcare Conference coming up. That might increase the volume and keep the momentum going. After the share price has stayed above $1 for 10 days the fear of Nasdaq compliance will disappear and any positive news will have this heading higher. New CEO, $12 price target, fast track designation, SABBY just increased their stake in DelMar to nearly 10% of the company. Things will happen here.
I think it took the hiring of the new CEO, Dan O'Connor to get this ship pointed in the right direction. He said it himself that the recently presented data was the only reason he joined Oncosec, so I believe that he truly believes he can make a successful pipeline happen here. 2 IST trials with anti-pd1 (no cost to Oncosec and obviously drug provided by Merck), TNBC trial (might be with Opdivo drug supply from Bristol Myers...according to an unconfirmed twitter message).....we will see. Also PIIM trial and probably collaborations and partnerships on the horizon. SITC data in November definitely shook things up a bit. 2018 is gonna be great for Oncosec.....and it has been a long time coming. Glad I am still a shareholder too. Good Luck Ahab!
Jeff, the 2018 Outlook PR was outstanding so I am not surprised we are above $2 now. We now have multiple catalysts to get the share price moving besides PISCES data. We are looking very good this year. The new CEO is not fooling around or wasting time getting the ball rolling.
DelMar making a big move now. Looks good in 2018. They have a huge opportunty in Brain Cancer. The market is waking up to just how undervalued the stock is right now.
Jeff, the updates for 2018 look impressive to me. I like that they are going to do 2 Investigator Sponsored Trials in Head and Neck which means Oncosec is not paying for them.....and starting a phase 2 TNBC trial. I think a lot of transformational events happen in 2018. We will be well over $2 very soon if not by the end of this day.
More important is that Oncosec release positive interim PISCES data next year which leads to a fast track FDA approval and commercialization in 2019. The cutback on orphan drug write-offs sucks but at least orphan drugs still carry 7 years of exclusivity. I don't think Merck will mind that much when they buyout Oncosec.
Good point hschlauch. That would get the ball rolling while we wait for PISCES data without any more dilution if another trial starts up before then.
They are planning something. Can't wait to see what 2018 brings us. Exciting times for Oncosec. We just need a concrete financial partnering. Good PISCES data and Merck will be all in and no need to worry...the rest will take care of itself. I hope a partnering happens before PISCES data but if it doesn't we just wait a little longer I guess.
Regarding the article published a few days ago, Algazi mentioned starting a new study for Head and Neck cancer based on the positive data presented at SITC. I would assume it would follow the same protocol as the PISCES trial...and Merck providing Keytruda. Wondering if this time Merck provides upfront cash.
Jeff, I don't think it was mentioned which site the first patient was dosed at. I do know that the Australian subsidiary of Oncosec was created because of financial benefit there as well as the high rate of melanoma.
7 recruiting sites now open for PISCES trial. Moving along nicely now. https://clinicaltrials.gov/ct2/show/NCT03132675?term=NCT03132675&rank=1
Market might not be excited about a single patient starting treatment. More patients may be enrolled now but haven't been dosed yet. The negative price action on the news might have the market nervous about getting data by mid 2018. Might be more realistic to expect data by end of 2018 on fully enrolled and treated 23 patients of first phase of trial. Any price weakness going into 2018 is a great buying opportunity in my opinion.
Looking over the recent SEC filing Oncosec has about $22 million right now which includes the $9.3 million in warrant money raised.
Warrant Exercises
During the three months ended October 31, 2017, we received an immaterial amount of cash related to the exercise of outstanding warrants, and subsequent to October 31, 2017, we received gross proceeds of $9.3 million from the exercise of outstanding warrants (see “—November 2017 Warrant Exercise Inducement Offering” above). If the holders of all of our warrants that are outstanding as of the issuance of this report were to exercise all such warrants in full on a cash basis, we would receive an aggregate of approximately $27.4 million in net proceeds. However, the holders of these warrants may choose to exercise only a portion of the warrants they hold, may choose not to exercise any of the warrants they hold, or may choose to “net” exercise their warrants on a cashless basis to the extent permitted by the warrants. As a result, we may never receive meaningful, or any, proceeds from the exercise of these warrants.
If Oncosec reports good interim PISCES data mid-2018 this will probably trigger the outstanding warrants to be executed which will result in Oncosec banking another $27.4 million. Dilution should not be a problem because good results should lead to a licensing deal or buyout. If not, Oncosec will have around $40 million dollars to get commercialization started on their own....but that is absolutely not their intention. Dan O'Connor will make a deal....bank on it!
Kevin Hellevoet from KU Leuven will be speaking at the 2nd Annual Next Gen Oncology Congress-(13th and 14th March 2018). Oncosec might also be speaking or presenting too. This might be where we get some interesting news about the multi-gene construct or collaboration with KU Leuven.
http://events.marketsandmarkets.com/2nd-Annual-Next-Gen-Immuno-Oncology-Congress#Agenda
Titan, I think that will be a major turning point for Oncosec. We just need that good PISCES data and the rest will take care of itself. This short-term pain is nothing compared to the rewards later on.
Oncosec has more than $20 million now....so I see no more dilution for a while unless of course we get some great data news on TNBC or a collaboration that quickly moves the share price up. I also don't see the worry about the warrants being executed until the share price is much higher either. 2018 will be great.....if we go sideways for a bit I would suggest adding more shares at a discount before PISCES data.
Could be. Shorts taking profits or longs taking a loss before year end. That is what happens in December with no more news to keep the adrenaline going.
Oncosec has raised the cash needed to get them to Interim PISCES data mid-2018. If results are good the price will rise significantly, remaining warrants will probably be executed and Oncosec will bank a lot more money from those warrants (if all warrants are executed-around $26 million dollars according to the latest SEC filing). 2018 will be all about the data and/or partnering. A collaboration, licensing deal, or partnership for TNBC or multi-gene construct before PISCES data would be an added bonus to get the shares moving again......if that doesn't happen then it is all about the PISCES data in 2018. I really hope we see something extra to boot though. If PISCES data is good I would expect a partnership/licensing deal with Merck to be announced....maybe even a buyout. If any of these things unfold then I think there is no need to worry about further dilution at this point.
I agree Jeff. I think Punit has done an excellent job taking Oncosec from the OTC to Nasdaq and attracting top talent. When Dr. Robert Pierce joined I knew they had something to keep an eye on. The market has not been kind to Oncosec, but the addition of Dan O'Connor as the new CEO will mark a major change in things heading into 2018. PISCES data will be a game-changer. The first part of 2018 we might languish a bit until either a collaboration on the multi-gene construct or something else. PISCES data will definitely be the big share price moving event to wait for.
Wildfire Forces Cancellation of LD Micro Conference. Might be the reason for Oncosec slumping today....or execution of warrants.
With all the recent SEC filings I think this is being orchestrated before any more positive news is released soon.
I hope this is because the warrants are being executed. If so, I would expect a PR from Oncosec when done and we can begin a move higher.
Hope you are right, today was ugly.
Looking forward to seeing Oncosec put theory to the test in a deep solid tumor combo trial such as TNBC...in partnership with Merck or another company with anti PD-1. Both abstracts from SITC suggest that we are about to make a new leap to a higher level in response rates...it's coming...we just don't know how soon.
Thanks Jeff. If that is what is happening now with the slow drift down we should be out of the woods soon with the selling pressure. The stock chart is looking like a tight wedge shape. Looks like consolidation to me. I think we will have another sharp move higher once the pressure is off. ....hopefully.